News & Updates

Monoclonal antibodies vs COVID-19 up risks of hepatotoxicity, neutropenia
Monoclonal antibodies vs COVID-19 up risks of hepatotoxicity, neutropenia
08 May 2025 byStephen Padilla

Treatment with monoclonal antibodies (mAbs) among COVID-19 patients is associated with a higher risk of hepatotoxicity and neutropenia when compared with standard of care (SoC) or placebo, reports a study.

Monoclonal antibodies vs COVID-19 up risks of hepatotoxicity, neutropenia
08 May 2025
BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization
BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization
06 May 2025 byKanas Chan

BNT162b2 JN.1-adapted vaccine provides protection against COVID-19–related hospitalization in Europe, a case-control study using the id.DRIVE platform has shown.

BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization
06 May 2025
MSC therapy delivers long-term benefit in severe COVID-19
MSC therapy delivers long-term benefit in severe COVID-19
02 May 2025 byAudrey Abella

A recent study suggests patients with severe COVID-19 may benefit from human mesenchymal stem cell (MSC) therapy.

MSC therapy delivers long-term benefit in severe COVID-19
02 May 2025
Single-dose baloxavir reduces household transmission of influenza
Single-dose baloxavir reduces household transmission of influenza
30 Apr 2025 byNatalia Reoutova

A single dose of baloxavir given to an index patient (IP) reduces the odds of influenza transmission to untreated household contacts (HHCs) by 32 percent vs placebo, according to the results of the phase IIIb CENTERSTONE trial.

Single-dose baloxavir reduces household transmission of influenza
30 Apr 2025